BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million

Reuters01-12

BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million

BioCryst Pharmaceuticals Inc. reported preliminary, unaudited net revenue for its flagship product ORLADEYO (berotralstat) of $601 million for the full year 2025, representing a 37 percent year-over-year increase and surpassing its prior guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue, full-year 2025 net revenue was $563 million, up 43 percent on a comparable basis. For the fourth quarter of 2025, ORLADEYO net revenue reached $151 million, a 22 percent year-over-year rise, or 36 percent when excluding European revenue. Looking ahead, BioCryst expects ORLADEYO net revenue to be between $625 million and $645 million in 2026. The company also anticipates continued non-GAAP profitability in 2026, even after the expected close of its proposed acquisition of Astria Therapeutics in the first quarter of 2026. Non-GAAP operating expenses, including the Astria acquisition, are projected to be between $450 million and $470 million for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623539-en) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602951464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602951464","market":"fut","top_or_hot":-1,"title":"BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioCryst Pharmaceuticals Inc. reported preliminary, unaudited net revenue for its flagship product ORLADEYO (berotralstat) of $601 million for the full year 2025, representing a 37 percent year-over-year increase and surpassing its prior guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue, full-year 2025 net revenue was $563 million, up 43 percent on a comparable basis. For the fourth quarter of 2025, ORLADEYO net revenue reached $151 million, a 22 percent year-over-year rise, or 36 percent when excluding European revenue. Looking ahead, BioCryst expects ORLADEYO net revenue to be between $625 million and $645 million in 2026. The company also anticipates continued non-GAAP profitability in 2026, even after the expected close of its proposed acquisition of Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in the first quarter of 2026. Non-GAAP operating expenses, including the Astria acquisition, are projected to be between $450 million and $470 million for 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623539-en) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioCryst Pharmaceuticals Inc. reported preliminary, unaudited net revenue for its flagship product ORLADEYO (berotralstat) of $601 million for the full year 2025, representing a 37 percent year-over-year increase and surpassing its prior guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue, full-year 2025 net revenue was $563 million, up 43 percent on a comparable basis. For the fourth quarter of 2025, ORLADEYO net revenue reached $151 million, a 22 percent year-over-year rise, or 36 percent when excluding European revenue. Looking ahead, BioCryst expects ORLADEYO net revenue to be between $625 million and $645 million in 2026. The company also anticipates continued non-GAAP profitability in 2026, even after the expected close of its proposed acquisition of Astria <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in the first quarter of 2026. Non-GAAP operating expenses, including the Astria acquisition, are projected to be between $450 million and $470 million for 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623539-en) on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL551Ybs:1","article_id":"2602951464","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602951464","pubTimestamp":1768219253,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioCryst Pharmaceuticals Inc. reported preliminary, unaudited net revenue for its flagship product ORLADEYO  of $601 million for the full year 2025, representing a 37 percent year-over-year increase and surpassing its prior guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue, full-year 2025 net revenue was $563 million, up 43 percent on a comparable basis. For the fourth quarter of 2025, ORLADEYO net revenue reached $151 million, a 22 percent year-over-year rise, or 36 percent when excluding European revenue. Looking ahead, BioCryst expects ORLADEYO net revenue to be between $625 million and $645 million in 2026. The company also anticipates continued non-GAAP profitability in 2026, even after the expected close of its proposed acquisition of Astria Therapeutics in the first quarter of 2026. Non-GAAP operating expenses, including the Astria acquisition, are projected to be between $450 million and $470 million for 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","NDAQ":"纳斯达克OMX交易所","BK4547":"WSB热门概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4588":"碎股","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","ATXS":"Astria Therapeutics Inc","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"BioCryst预计2026年ORLADEYO收入为6.25亿美元至6.45亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BCRX":0.9,"ATXS":0.9},"content_text":"BioCryst Projects 2026 ORLADEYO Revenue of $625 Million to $645 Million\n    \n\n        BioCryst Pharmaceuticals Inc. reported preliminary, unaudited net revenue for its flagship product ORLADEYO (berotralstat) of $601 million for the full year 2025, representing a 37 percent year-over-year increase and surpassing its prior guidance range of $590 million to $600 million. Excluding European ORLADEYO revenue, full-year 2025 net revenue was $563 million, up 43 percent on a comparable basis. For the fourth quarter of 2025, ORLADEYO net revenue reached $151 million, a 22 percent year-over-year rise, or 36 percent when excluding European revenue. Looking ahead, BioCryst expects ORLADEYO net revenue to be between $625 million and $645 million in 2026. The company also anticipates continued non-GAAP profitability in 2026, even after the expected close of its proposed acquisition of Astria Therapeutics in the first quarter of 2026. Non-GAAP operating expenses, including the Astria acquisition, are projected to be between $450 million and $470 million for 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623539-en) on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602951464","isCrawlerRequest":true}